Zelluna ASA: Notice of EGM - experienced international biotech executive proposed for election to the Board and Board member steps down  

Oslo,  17 August 2026: The  Board of  Directors of  Zelluna ASA  (the "Company")
hereby  calls for  an Extraordinary  General Meeting  to be  held on 9 September
2026 at 13:00 CEST, regarding election of a new member of the Company's Board of
Directors (the "Board").

The  Nomination Committee  has proposed  Martin Welschof  for election  as a new
member  of  the  Board.  Martin  Welschof  is  CEO of BioInvent International AB
(Nasdaq  Stockholm) and has previously served as  CEO of Affitech A/S and Opsona
Therapeutics.  He  holds  a  PhD  in  recombinant antibody technology and brings
extensive  international experience from  executive leadership in clinical-stage
and  listed biotechnology companies, including clinical development, partnering,
transactions and capital markets.

"The Nomination Committee has put forward a strong candidate, and we are pleased
to  present Martin to our shareholders," said  Anders Tuv, Chair of the Board of
Zelluna  ASA.  "He  brings  extensive  experience  from  leading  clinical-stage
biotechnology   companies,   alongside  significant  experience  in  partnering,
transactions  and the public markets. Should  the General Meeting elect him, his
experience would be a valuable addition to the Board as Zelluna advances through
clinical development and the next stage of its corporate development "

Hans  Ivar Robinson, who co-founded  the Company in 2016, and  has served on the
board since its foundation, has decided to step down from the Board in line with
Birk  Venture's  approach  of  transitioning  out  of  board  positions within a
reasonable  period following a  listing. His resignation  from the Board is with
immediate effective.

"I  am proud  of what  Zelluna has  achieved," said  Hans Ivar Robinson. "Having
served  on the Board since the Company was  founded, I believe this is a natural
point  to hand over  to others as  Zelluna enters this  exciting phase. I remain
confident  in Zelluna's leadership and the  opportunities ahead for the Company,
and I look forward to following its continued progress"

"On  behalf of the  Board, I would  like to thank  Hans Ivar for his significant
contribution to Zelluna since its foundation," said Anders Tuv. "As a co-founder
and  long-standing  Board  member,  he  has  played  an  important  role  in the
development  of the Company. We are grateful  for his commitment to Zelluna over
many years and wish him every success for the future."

The  General Meeting will  be held as  a digital meeting  only, with no physical
attendance  for  shareholders.  All  documents  to  be  processed in the General
Meeting,  as  well  as  the  participation  link  and  the Recommendation by the
Nomination  Committee, are available at the Company's website at www.zelluna.com
(http://www.zelluna.com).

For further information, please visit www.zelluna.com or contact:

Anders Tuv, Chair of the board
Email: anders@clairon.no (mailto:anders@clairon.no)
Phone: +47 982 06 826

This information is published in accordance with the disclosure requirements set
out in the Norwegian Securities Trading Act section 5-12.

About Zelluna ASA

Zelluna ASA (OSE: ZLNA) is a Company pioneering allogeneic 'off-the-shelf' T
Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of
solid cancers. The company's platform combines the innate killing power of NK
cells with precise solid tumour targeting of TCRs, designed to address the
limitations of current cell therapies in solid tumours. The company's lead
candidate, ZI-MA4-1, is the world's first MAGE-A4 targeting TCR-NK therapy in
clinical development. Zelluna is headquartered at the Oslo Cancer Cluster
Innovation Park in Oslo, Norway and is listed on the Euronext Oslo Stock
Exchange under the ticker ZLNA.